ScholarIQanswers from OpenAlex & ORCID
C.E.M. Griffiths
ResearcherPublications, citations & collaboration network
C.E.M. Griffiths is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does C.E.M. Griffiths have?
ScholarIQindexed works
C.E.M. Griffiths has 1,258 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does C.E.M. Griffiths have?
ScholarIQcitation count
C.E.M. Griffiths has 70,198 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of C.E.M. Griffiths?
ScholarIQh-index
C.E.M. Griffiths has an h-index of 129 in OpenAlex.
What is the i10-index of C.E.M. Griffiths?
ScholarIQi10-index
C.E.M. Griffiths has an i10-index of 693 in OpenAlex.
What is the ORCID of C.E.M. Griffiths?
ScholarIQorcid
The ORCID for C.E.M. Griffiths is on the source record.
What is the OpenAlex record for C.E.M. Griffiths?
ScholarIQopenalex
The OpenAlex for C.E.M. Griffiths is on the source record.
What are the most-cited papers on C.E.M. Griffiths?
ScholarIQmost cited works
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Rosa Parisi, Ireny Iskandar, Evangelos Kontopantelis, Matthias Augustin, C.E.M. Griffiths, Darren M. Ashcroft
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Lam C. Tsoi, Sarah L. Spain, Jo Knight, Eva Ellinghaus, Philip E. Stuart, Francesca Capon, Jun Ding, Yanming Li, Trilokraj Tejasvi, Jóhann E. Guðjónsson, Hyun Min Kang, Michael H. Allen, Ross McManus, Giuseppe Novelli, Lena Samuelsson, Joost Schalkwijk, Mona Ståhle, A. David Burden, Catherine Smith, Michael J. Cork, Xavier Estivill, A. Bowcock, Gerald G. Krueger, Wolfgang Weger, Jane Worthington, Rachid Tazi‐Ahnini, Frank O. Nestlé, Adrian Hayday, Per Hoffmann, Juliane Winkelmann, Cisca Wijmenga, Cordelia Langford, Sarah Edkins, Robert Andrews, Hannah Blackburn, Amy Strange, Gavin Band, Richard D. Pearson, Damjan Vukcevic, Chris C. A. Spencer, Panos Deloukas, Ulrich Mrowietz, Stefan Schreiber, Stephan Weidinger, Sulev Kõks, Külli Kingo, Tõnu Esko, Andres Metspalu, Henry W. Lim, John J. Voorhees, Michael Weichenthal, H.‐Erich Wichmann, Vinod Chandran, Cheryl F. Rosen, Proton Rahman, Dafna D. Gladman, C.E.M. Griffiths, André Reis, Juha Kere, Rajan P. Nair, André Franke, Jonathan N W N Barker, Gonçalo R. Abecasis, James T Elder, Richard C. Trembath
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter